598 related articles for article (PubMed ID: 28374077)
1. Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
Wang J; Wu CJ; Bao ML; Zhang J; Wang XN; Zhang YD
Eur Radiol; 2017 Oct; 27(10):4082-4090. PubMed ID: 28374077
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
5. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.
Zhang L; Zhe X; Tang M; Zhang J; Ren J; Zhang X; Li L
Contrast Media Mol Imaging; 2021; 2021():7830909. PubMed ID: 35024015
[TBL] [Abstract][Full Text] [Related]
7. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
[TBL] [Abstract][Full Text] [Related]
8. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
[No Abstract] [Full Text] [Related]
9. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
11. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
[TBL] [Abstract][Full Text] [Related]
12. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
14. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
[TBL] [Abstract][Full Text] [Related]
15. Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer.
Li M; Yang L; Yue Y; Xu J; Huang C; Song B
Front Oncol; 2020; 10():631831. PubMed ID: 33680954
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI.
Iyama Y; Nakaura T; Katahira K; Iyama A; Nagayama Y; Oda S; Utsunomiya D; Yamashita Y
Eur Radiol; 2017 Sep; 27(9):3600-3608. PubMed ID: 28289941
[TBL] [Abstract][Full Text] [Related]
17. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
[TBL] [Abstract][Full Text] [Related]
18. Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
Bernatz S; Ackermann J; Mandel P; Kaltenbach B; Zhdanovich Y; Harter PN; Döring C; Hammerstingl R; Bodelle B; Smith K; Bucher A; Albrecht M; Rosbach N; Basten L; Yel I; Wenzel M; Bankov K; Koch I; Chun FK; Köllermann J; Wild PJ; Vogl TJ
Eur Radiol; 2020 Dec; 30(12):6757-6769. PubMed ID: 32676784
[TBL] [Abstract][Full Text] [Related]
19. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
[No Abstract] [Full Text] [Related]
20. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
